Compare Torrent Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs BIOCON - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA BIOCON TORRENT PHARMA/
BIOCON
 
P/E (TTM) x 57.4 25.2 227.6% View Chart
P/BV x 6.9 3.3 205.9% View Chart
Dividend Yield % 0.7 0.3 215.0%  

Financials

 TORRENT PHARMA   BIOCON
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
BIOCON
Mar-18
TORRENT PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,5501,188 130.5%   
Low Rs1,144305 374.9%   
Sales per share (Unadj.) Rs354.768.7 516.1%  
Earnings per share (Unadj.) Rs40.17.6 530.7%  
Cash flow per share (Unadj.) Rs64.214.0 459.7%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %1.00.1 776.0%  
Book value per share (Unadj.) Rs273.186.3 316.3%  
Shares outstanding (eoy) m169.22600.00 28.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.810.9 35.0%   
Avg P/E ratio x33.698.9 34.0%  
P/CF ratio (eoy) x21.053.4 39.2%  
Price / Book Value ratio x4.98.6 57.0%  
Dividend payout %34.913.2 263.8%   
Avg Mkt Cap Rs m227,897447,900 50.9%   
No. of employees `00014.76.1 239.1%   
Total wages/salary Rs m11,3539,311 121.9%   
Avg. sales/employee Rs Th4,083.06,705.8 60.9%   
Avg. wages/employee Rs Th772.31,514.2 51.0%   
Avg. net profit/employee Rs Th461.3736.9 62.6%   
INCOME DATA
Net Sales Rs m60,02141,234 145.6%  
Other income Rs m2,9882,062 144.9%   
Total revenues Rs m63,00943,296 145.5%   
Gross profit Rs m13,4938,291 162.7%  
Depreciation Rs m4,0863,851 106.1%   
Interest Rs m3,085615 501.6%   
Profit before tax Rs m9,3105,887 158.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5291,569 161.2%   
Profit after tax Rs m6,7814,531 149.7%  
Gross profit margin %22.520.1 111.8%  
Effective tax rate %27.226.7 101.9%   
Net profit margin %11.311.0 102.8%  
BALANCE SHEET DATA
Current assets Rs m52,62341,486 126.8%   
Current liabilities Rs m52,02221,413 242.9%   
Net working cap to sales %1.048.7 2.1%  
Current ratio x1.01.9 52.2%  
Inventory Days Days12064 187.0%  
Debtors Days Days7694 80.9%  
Net fixed assets Rs m85,01650,661 167.8%   
Share capital Rs m8463,000 28.2%   
"Free" reserves Rs m45,37648,808 93.0%   
Net worth Rs m46,22251,808 89.2%   
Long term debt Rs m41,11517,898 229.7%   
Total assets Rs m142,43299,897 142.6%  
Interest coverage x4.010.6 38.0%   
Debt to equity ratio x0.90.3 257.5%  
Sales to assets ratio x0.40.4 102.1%   
Return on assets %6.95.2 134.5%  
Return on equity %14.78.7 167.8%  
Return on capital %14.29.6 147.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58012,058 120.9%   
Fx outflow Rs m3,6007,348 49.0%   
Net fx Rs m10,9804,710 233.1%   
CASH FLOW
From Operations Rs m8,9426,621 135.1%  
From Investments Rs m-47,070-6,840 688.2%  
From Financial Activity Rs m34,174-2,397 -1,425.7%  
Net Cashflow Rs m-3,655-2,612 139.9%  

Share Holding

Indian Promoters % 71.5 40.4 177.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.0 8.4 83.6%  
FIIs % 12.6 10.7 117.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 19.9 44.2%  
Shareholders   26,511 109,995 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

RBI Monetary Policy, US-China Trade War, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended marginally lower yesterday. Benchmark indices gave up gains after the central bank kept its policy rate unchanged.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 6, 2019 09:23 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS